Technical Analysis for GKOS - Glaukos Corporation

Grade Last Price % Change Price Change
A 118.35 0.83% 0.97
GKOS closed up 0.83 percent on Friday, June 28, 2024, on 2.51 times normal volume. The bulls were able to push the stock to a new 52-week high. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
1 Watcher
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Up

Date Alert Name Type % Chg
MACD Bullish Signal Line Cross Bullish 0.00%
New 52 Week Closing High Bullish 0.00%
New Uptrend Bullish 0.00%
Pocket Pivot Bullish Swing Setup 0.00%
Bollinger Band Squeeze Range Contraction 0.00%
Doji - Bearish? Reversal 0.00%
New 52 Week High Strength 0.00%
Upper Bollinger Band Walk Strength 0.00%
BB Squeeze + Upper Band Touch Range Contraction 0.00%
Above Upper BB Strength 0.00%

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Glaukos Corporation Description

Glaukos Corporation (Glaukos) is an ophthalmic medical technology company. The Company is engaged in the development and commercialization of products and procedures for the treatment of glaucoma. Glaukos has developed the micro-invasive glaucoma surgery (MIGS) for glaucoma treatment. It offers iStent, an MIGS device measuring one millimeter long and 0.33 millimeter wide. MIGS procedures involve the insertion of a micro-scale device from within the eye's anterior chamber through a small corneal incision. Glaukos is also engaged in developing a portfolio of micro-scale injectable therapies, including three pipeline products, namely, the iStent Inject, the iStent Supra and iDose. The iStent Inject includes two stents pre-loaded in an auto-injection inserter. The iStent Supra is designed to access an alternative drainage space within the eye. iDose is an implant that is designed to provide a sustained release of a prostaglandin drug to lower intraocular pressure in glaucoma patients.


Classification

Sector: Healthcare
Industry: Medical Instruments & Supplies
Keywords: Medicine Eye Surgery Medical Technology Ophthalmology Ophthalmic Drainage Glaucoma Vision Implant Blindness Incision Treatment Of Glaucoma Eye Surgery Cornea Intraocular Pressure

Is GKOS a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 119.89
52 Week Low 59.22
Average Volume 477,586
200-Day Moving Average 87.11
50-Day Moving Average 108.62
20-Day Moving Average 113.70
10-Day Moving Average 113.95
Average True Range 3.29
RSI (14) 68.65
ADX 26.0
+DI 30.43
-DI 13.18
Chandelier Exit (Long, 3 ATRs) 110.01
Chandelier Exit (Short, 3 ATRs) 117.55
Upper Bollinger Bands 117.30
Lower Bollinger Band 110.11
Percent B (%b) 1.15
BandWidth 6.33
MACD Line 2.06
MACD Signal Line 1.88
MACD Histogram 0.1807
Fundamentals Value
Market Cap 5.78 Billion
Num Shares 48.8 Million
EPS -2.69
Price-to-Earnings (P/E) Ratio -44.00
Price-to-Sales 15.43
Price-to-Book 9.83
PEG Ratio 1.64
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 123.63
Resistance 3 (R3) 123.56 121.72 122.75
Resistance 2 (R2) 121.72 120.38 121.76 122.46
Resistance 1 (R1) 120.04 119.55 120.88 120.11 122.16
Pivot Point 118.20 118.20 118.63 118.24 118.20
Support 1 (S1) 116.52 116.86 117.36 116.59 114.54
Support 2 (S2) 114.68 116.03 114.72 114.24
Support 3 (S3) 113.00 114.68 113.95
Support 4 (S4) 113.07